OwnershipPublicly listed · Nasdaq: TWSTSEC EDGAR company record and tickers file (Nasdaq: TWST) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as Nasdaq: TWST, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
7developments published
$6.7MUS federal obligations on record
21federal awards
Aug 4, 2026latest development
Timeline
- Aug 4, 2026 · Financing
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Company-reported - Aug 3, 2026 · Reported results
Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results
Company-reported - Jul 30, 2026 · Government award
National Institutes of Health obligates $26,754 to Twist Bioscience
Government record - Jun 30, 2026 · Government award
Department of Veterans Affairs obligates $47,450 to Twist Bioscience
Government record - Jun 29, 2026 · Government award
Federal Bureau of Investigation obligates $97,120 to Twist Bioscience
Government record - Jun 8, 2026 · Government award
Department of the Navy obligates $50,385 to Twist Bioscience
Government record - May 4, 2026 · Reported results
Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results
Company-reported
Profile
- Legal name
- Twist Bioscience Corp
- Listing
- Nasdaq TWST
- SEC filer
- CIK 0001581280 ↗
- SEC industry code
- Biological Products, (No Diagnostic Substances)
- Incorporated
- DE
- Coverage
- Filings + federal awards
Mix of developments
Watch Twist Bioscience
Anything new from Twist Bioscience lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestUS federal awards
From USAspending.gov. Obligated is money the government has committed, not company revenue and not the contract’s potential ceiling. Outlays is what has actually been paid. Totals: $6.7 million obligated, $6.4 million paid out across 21 awards.
| Agency | Description | Obligated | Paid out | Period | Record |
|---|---|---|---|---|---|
| National Institutes of Health | RADX TECH PROJECT 6818 PORTABLE, RAPID, DISPOSABLE TEST WITH SYNTHETIC ANTIBODIES FOR TESTING ANYWHERE | $5.0 million | $5.0 million | Nov 10, 2021 – Nov 9, 2023 | USAspending ↗ |
| Centers for Disease Control and Prevention | SC2 POSITIVE CONTROL SYNTHETIC RNA CONTROL MATERIAL | $540,143 | $540,143 | Mar 11, 2021 – Sep 1, 2021 | USAspending ↗ |
| Centers for Disease Control and Prevention | SC2 POSITIVE CONTROL SYNTHETIC RNA CONTROL | $263,625 | $263,625 | Feb 4, 2021 – Jul 1, 2021 | USAspending ↗ |
| Centers for Disease Control and Prevention | LAP SUPPLIES | $157,390 | $157,390 | Sep 15, 2024 – Sep 14, 2025 | USAspending ↗ |
| Centers for Disease Control and Prevention | SARS COV2 RNA CONTROL | $125,563 | $125,563 | Dec 8, 2020 – Jan 1, 2021 | USAspending ↗ |
| Department of Veterans Affairs | SHAHRARA HUMANIZED MONOCLONAL ANTIBODY FOR SYNDECAN TWIST BIOSCIENCE | $104,607 | Not stated | Sep 18, 2024 – Sep 14, 2025 | USAspending ↗ |
| Federal Bureau of Investigation | TWIST BIOSCIENCE EQUIPMENT | $97,120 | $97,120 | Jun 29, 2026 – Jul 20, 2026 | USAspending ↗ |
| Department of Veterans Affairs | FFPE SAMPLING | $64,140 | Not stated | Jul 11, 2024 – Nov 14, 2024 | USAspending ↗ |
Showing the 8 largest of 21 awards on record.